Cellegy Pharmaceuticals Inc, Rebound? - 500 Beiträge pro Seite
eröffnet am 16.11.06 15:51:47 von
neuester Beitrag 09.02.07 09:18:33 von
neuester Beitrag 09.02.07 09:18:33 von
Beiträge: 2
ID: 1.094.936
ID: 1.094.936
Aufrufe heute: 0
Gesamt: 589
Gesamt: 589
Aktive User: 0
ISIN: US15115L1035 · WKN: 903551
Feedback
Schaut selbst von wo der Titel herkommt und was in den News steht.
Denke mal hier sind einpaar schnelle Dolar's drin.
Cellegy Reports September 30, 2006 Quarter Financial Results
QUAKERTOWN, Penn., Nov. 15 /PRNewswire-FirstCall/ -- Cellegy Pharmaceuticals, Inc. (CLGY.OB) announced its third quarter 2006 financial results today.
Revenues for the three months ended September 30, 2006 were $172,000 compared to $1,738,000 during the same period in 2005. Prior year revenues for the third quarter included $1,252,000 in Biosyn grant revenue, $257,000 in product sales and $109,000 in licensing revenues.
Revenues for the nine months ended September 30, 2006 were $2,635,000 compared to $10,804,000 for the same period in 2005. These included licensing revenues of $452,000 and $6,950,000 for the nine months ended September 30, 2006 and 2005, respectively.
Research and development expenses for the three months ended September 30, 2006 and 2005, were $338,000 and $1,816,000, respectively. The decrease was primarily attributable to reduction in research and development salary expense, professional fees and clinical testing expenses.
Research and development expenses for the nine months ended September 30, 2006 and 2005 were $2,244,000 and $6,855,000, respectively. The decrease was primarily attributable to current period reductions in research and development salary expense, professional fees and clinical testing fees.
Selling, general and administrative expenses for the quarter ended September 30, 2006 and 2005 were $955,000 and $2,471,000, respectively. The decrease of $1,350,000 was primarily attributable to current period reductions in SG&A salary expense and operating expenses.
For the nine months ended September 30, 2006 and 2005, selling, general and administrative expenses were $4,526,000 and $6,764,000, respectively. The decrease resulted primarily from a reduction in litigation and other related expenses.
Net loss from continuing operations for the quarter ended September 30, 2006 was $1,640,000 or ($0.05) per basic and diluted common share based on 29,833,000 shares. Cellegy had a net loss of $2,867,000 or ($0.10) per basic and diluted common share based on 29,832,000 shares during the same three- month period in 2005.
The Company had cash and cash equivalents of $830,000 at September 30, 2006 compared to $2,251,000 at December 31, 2005 and $2,305,000 at September 30, 2005.
Due to its cash position and negative operating cash flows, Cellegy received a going concern qualification in the report of its independent registered public accounting firm included in the Annual Report on Form 10-K for the year ended December 31, 2005. Cellegy believes that available cash resources will be adequate to satisfy its capital needs through at least the end of November 2006. Subject to the terms and conditions of the Asset Purchase Agreement with Strakan International Limited, the Company has agreed to sell to ProStrakan all of its right, title and interest in and to the assets used in connection with or relating to the research, development and commercialization of nitroglycerin/nitric oxide and other related pharmacological products for pain management applications and testosterone gels for treatment of male hypogonadism, and for certain female sexual dysfunction conditions, as currently conducted and as currently proposed to be conducted by Cellegy, including those assets relating to Cellegy's nitroglycerin/nitric oxide and related pharmacological products marketed under the name Rectogesic(R) and proposed to be marketed under the name Cellegesic(R) and Cellegy's testosterone gels marketed under the name Tostrex(TM) and proposed to be marketed under the names Tostran(TM) or Fortigel(TM) and Cellegy's product candidate Tostrelle.
A special meeting of stockholders to consider and vote on the proposed transaction with ProStrakan is scheduled to be held on November 22, 2006. There is no assurance that the proposed transaction will be approved by the shareholders. If the proposed transaction is not approved by the shareholders, a significant portion of the Company's liabilities would become immediately due and payable, including promissory notes reflecting amounts due to PDI, Inc. and ProStrakan. In this event, the Company would most likely be unable to meet its obligations to its creditors.
About Cellegy
Cellegy Pharmaceuticals is a specialty biopharmaceutical company that develops and commercializes prescription drugs for the treatment of women's health care conditions, including sexual dysfunction, HIV prevention and gastrointestinal disorders. Savvy(R) (C31G vaginal gel), a novel microbicide gel product for contraception and the reduction in transmission of HIV in women, is currently undergoing a Phase 3 clinical study in the United States for contraception.
Forward-Looking Statements
This press release contains forward-looking statements. Investors are cautioned that these forward-looking statements are subject to numerous risks and uncertainties, known and unknown, which could cause actual results and developments to differ materially from those expressed or implied in such statements. For more information regarding risk factors, refer to the Company's Annual Report on Form 10-K for the year ended December 31, 2005, Quarterly Report on Form 10-Q for the quarter ended June 30, 2006 and other filings with the Securities and Exchange Commission.
Where to find additional information about the transaction
Cellegy has filed a definitive proxy statement with the Securities and Exchange Commission in connection with the proposed transaction with ProStrakan. BEFORE MAKING ANY VOTING OR INVESTMENT DECISION, CELLEGY'S STOCKHOLDERS ARE URGED TO READ THE PROXY STATEMENT REGARDING THE PROPOSED TRANSACTION CAREFULLY AND IN ITS ENTIRETY BECAUSE IT CONTAINS IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION. Investors and stockholders may obtain free copies of the proxy statement and other relevant documents (when they become available) and other documents filed with the Securities and Exchange Commission at the Securities and Exchange Commission's web site at: www.sec.gov. In addition, investors and stockholders may obtain free copies of the documents filed with the Securities and Exchange Commission by Cellegy by contacting the persons identified below. Cellegy's directors and executive officers may be deemed to be participants in the solicitation of proxies from its stockholders in connection with the proposed transaction. Information regarding the interests of directors and executive officers in the transaction is included in the proxy statement of the Company. Additional information regarding directors and executive officers of Cellegy is also included in the Company's annual report on Form 10-K for the year ended December 31, 2005, filed with the Securities and Exchange Commission, which is available as described above.
CELLEGY PHARMACEUTICALS, INC.
SUMMARY OF FINANCIAL RESULTS
SEPTEMBER 30, 2006
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Amounts in thousands)
Period from
Three Months Nine Months June 26, 1989
Ended Ended (inception) to
September 30, September 30, September 30,
2006 2005 2006 2005 2006
Total revenues $172 $1,738 $2,635 $10,804 $25,832
Costs and expenses:
Cost of product
sales -- 197 257 241 1,945
Research and
development 338 1,816 2,244 6,855 92,207
Selling, general and
administrative 955 2,471 4,526 6,764 50,624
Equipment FMV
adjustment 276 -- 276 -- 276
Acquired in-process
technology -- -- -- -- 22,332
Total costs and
expenses 1,569 4,484 7,303 13,860 167,384
Operating income
(loss) (1,397) (2,746) (4,668) (3,054) (141,552)
Interest and other
income 99 17 114 121 7,144
Interest and other
expense (487) (217) (924) (478) (3,082)
Derivative
revaluation 145 79 170 243 1,250
Net income (loss) (1,640) (2,867) (5,308) (3,169) (136,240)
Non-cash Preferred
Dividends -- -- -- -- (1,449)
Net income (loss)
from continuing
operations
applicable to
common stockholders $(1,640) $(2,867) $(5,308) $(3,169) $(137,689)
Net income (loss)
per common share:
Basic $(0.05) $(0.10) $(0.18) $(0.11)
Diluted $(0.05) $(0.10) $(0.18) $(0.11)
Weighted average
number of common
shares used in per
share calculations:
Basic 29,833 29,832 29,832 28,048
Diluted 29,833 29,832 29,832 28,048
CELLEGY PHARMACEUTICALS, INC.
SUMMARY OF FINANCIAL RESULTS
SEPTEMBER 30, 2006
CONDENSED CONSOLIDATED BALANCE SHEETS
(Amounts in thousands)
September 30, December 31,
2006 2005
Assets
Current assets:
Cash and investments $830 $2,262
Other assets 415 4,188
Total assets $1,245 $6,450
Liabilities and Stockholders' Deficit
Total current liabilities $9,120 $9,437
Deferred revenue 3,349 3,084
Other long-term payable and
derivative instrument 310 405
Stockholders' deficit (11,534) (6,477)
Total liabilities and stockholders'
deficit $1,245 $6,450
SOURCE Cellegy Pharmaceuticals, Inc.
Source: PR Newswire (November 15, 2006 - 5:00 PM EST)
News by QuoteMedia
www.quotemedia.com
Denke mal hier sind einpaar schnelle Dolar's drin.
Cellegy Reports September 30, 2006 Quarter Financial Results
QUAKERTOWN, Penn., Nov. 15 /PRNewswire-FirstCall/ -- Cellegy Pharmaceuticals, Inc. (CLGY.OB) announced its third quarter 2006 financial results today.
Revenues for the three months ended September 30, 2006 were $172,000 compared to $1,738,000 during the same period in 2005. Prior year revenues for the third quarter included $1,252,000 in Biosyn grant revenue, $257,000 in product sales and $109,000 in licensing revenues.
Revenues for the nine months ended September 30, 2006 were $2,635,000 compared to $10,804,000 for the same period in 2005. These included licensing revenues of $452,000 and $6,950,000 for the nine months ended September 30, 2006 and 2005, respectively.
Research and development expenses for the three months ended September 30, 2006 and 2005, were $338,000 and $1,816,000, respectively. The decrease was primarily attributable to reduction in research and development salary expense, professional fees and clinical testing expenses.
Research and development expenses for the nine months ended September 30, 2006 and 2005 were $2,244,000 and $6,855,000, respectively. The decrease was primarily attributable to current period reductions in research and development salary expense, professional fees and clinical testing fees.
Selling, general and administrative expenses for the quarter ended September 30, 2006 and 2005 were $955,000 and $2,471,000, respectively. The decrease of $1,350,000 was primarily attributable to current period reductions in SG&A salary expense and operating expenses.
For the nine months ended September 30, 2006 and 2005, selling, general and administrative expenses were $4,526,000 and $6,764,000, respectively. The decrease resulted primarily from a reduction in litigation and other related expenses.
Net loss from continuing operations for the quarter ended September 30, 2006 was $1,640,000 or ($0.05) per basic and diluted common share based on 29,833,000 shares. Cellegy had a net loss of $2,867,000 or ($0.10) per basic and diluted common share based on 29,832,000 shares during the same three- month period in 2005.
The Company had cash and cash equivalents of $830,000 at September 30, 2006 compared to $2,251,000 at December 31, 2005 and $2,305,000 at September 30, 2005.
Due to its cash position and negative operating cash flows, Cellegy received a going concern qualification in the report of its independent registered public accounting firm included in the Annual Report on Form 10-K for the year ended December 31, 2005. Cellegy believes that available cash resources will be adequate to satisfy its capital needs through at least the end of November 2006. Subject to the terms and conditions of the Asset Purchase Agreement with Strakan International Limited, the Company has agreed to sell to ProStrakan all of its right, title and interest in and to the assets used in connection with or relating to the research, development and commercialization of nitroglycerin/nitric oxide and other related pharmacological products for pain management applications and testosterone gels for treatment of male hypogonadism, and for certain female sexual dysfunction conditions, as currently conducted and as currently proposed to be conducted by Cellegy, including those assets relating to Cellegy's nitroglycerin/nitric oxide and related pharmacological products marketed under the name Rectogesic(R) and proposed to be marketed under the name Cellegesic(R) and Cellegy's testosterone gels marketed under the name Tostrex(TM) and proposed to be marketed under the names Tostran(TM) or Fortigel(TM) and Cellegy's product candidate Tostrelle.
A special meeting of stockholders to consider and vote on the proposed transaction with ProStrakan is scheduled to be held on November 22, 2006. There is no assurance that the proposed transaction will be approved by the shareholders. If the proposed transaction is not approved by the shareholders, a significant portion of the Company's liabilities would become immediately due and payable, including promissory notes reflecting amounts due to PDI, Inc. and ProStrakan. In this event, the Company would most likely be unable to meet its obligations to its creditors.
About Cellegy
Cellegy Pharmaceuticals is a specialty biopharmaceutical company that develops and commercializes prescription drugs for the treatment of women's health care conditions, including sexual dysfunction, HIV prevention and gastrointestinal disorders. Savvy(R) (C31G vaginal gel), a novel microbicide gel product for contraception and the reduction in transmission of HIV in women, is currently undergoing a Phase 3 clinical study in the United States for contraception.
Forward-Looking Statements
This press release contains forward-looking statements. Investors are cautioned that these forward-looking statements are subject to numerous risks and uncertainties, known and unknown, which could cause actual results and developments to differ materially from those expressed or implied in such statements. For more information regarding risk factors, refer to the Company's Annual Report on Form 10-K for the year ended December 31, 2005, Quarterly Report on Form 10-Q for the quarter ended June 30, 2006 and other filings with the Securities and Exchange Commission.
Where to find additional information about the transaction
Cellegy has filed a definitive proxy statement with the Securities and Exchange Commission in connection with the proposed transaction with ProStrakan. BEFORE MAKING ANY VOTING OR INVESTMENT DECISION, CELLEGY'S STOCKHOLDERS ARE URGED TO READ THE PROXY STATEMENT REGARDING THE PROPOSED TRANSACTION CAREFULLY AND IN ITS ENTIRETY BECAUSE IT CONTAINS IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION. Investors and stockholders may obtain free copies of the proxy statement and other relevant documents (when they become available) and other documents filed with the Securities and Exchange Commission at the Securities and Exchange Commission's web site at: www.sec.gov. In addition, investors and stockholders may obtain free copies of the documents filed with the Securities and Exchange Commission by Cellegy by contacting the persons identified below. Cellegy's directors and executive officers may be deemed to be participants in the solicitation of proxies from its stockholders in connection with the proposed transaction. Information regarding the interests of directors and executive officers in the transaction is included in the proxy statement of the Company. Additional information regarding directors and executive officers of Cellegy is also included in the Company's annual report on Form 10-K for the year ended December 31, 2005, filed with the Securities and Exchange Commission, which is available as described above.
CELLEGY PHARMACEUTICALS, INC.
SUMMARY OF FINANCIAL RESULTS
SEPTEMBER 30, 2006
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Amounts in thousands)
Period from
Three Months Nine Months June 26, 1989
Ended Ended (inception) to
September 30, September 30, September 30,
2006 2005 2006 2005 2006
Total revenues $172 $1,738 $2,635 $10,804 $25,832
Costs and expenses:
Cost of product
sales -- 197 257 241 1,945
Research and
development 338 1,816 2,244 6,855 92,207
Selling, general and
administrative 955 2,471 4,526 6,764 50,624
Equipment FMV
adjustment 276 -- 276 -- 276
Acquired in-process
technology -- -- -- -- 22,332
Total costs and
expenses 1,569 4,484 7,303 13,860 167,384
Operating income
(loss) (1,397) (2,746) (4,668) (3,054) (141,552)
Interest and other
income 99 17 114 121 7,144
Interest and other
expense (487) (217) (924) (478) (3,082)
Derivative
revaluation 145 79 170 243 1,250
Net income (loss) (1,640) (2,867) (5,308) (3,169) (136,240)
Non-cash Preferred
Dividends -- -- -- -- (1,449)
Net income (loss)
from continuing
operations
applicable to
common stockholders $(1,640) $(2,867) $(5,308) $(3,169) $(137,689)
Net income (loss)
per common share:
Basic $(0.05) $(0.10) $(0.18) $(0.11)
Diluted $(0.05) $(0.10) $(0.18) $(0.11)
Weighted average
number of common
shares used in per
share calculations:
Basic 29,833 29,832 29,832 28,048
Diluted 29,833 29,832 29,832 28,048
CELLEGY PHARMACEUTICALS, INC.
SUMMARY OF FINANCIAL RESULTS
SEPTEMBER 30, 2006
CONDENSED CONSOLIDATED BALANCE SHEETS
(Amounts in thousands)
September 30, December 31,
2006 2005
Assets
Current assets:
Cash and investments $830 $2,262
Other assets 415 4,188
Total assets $1,245 $6,450
Liabilities and Stockholders' Deficit
Total current liabilities $9,120 $9,437
Deferred revenue 3,349 3,084
Other long-term payable and
derivative instrument 310 405
Stockholders' deficit (11,534) (6,477)
Total liabilities and stockholders'
deficit $1,245 $6,450
SOURCE Cellegy Pharmaceuticals, Inc.
Source: PR Newswire (November 15, 2006 - 5:00 PM EST)
News by QuoteMedia
www.quotemedia.com
Warten wir noch bis nächste Woche 
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Investoren beobachten auch:
| Wertpapier | Perf. % |
|---|---|
| +0,08 | |
| +0,10 | |
| -0,54 | |
| -99,00 | |
| +0,06 | |
| - | |
| -2,38 | |
| -1,71 | |
| - | |
| - |
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 101 | ||
| 78 | ||
| 43 | ||
| 28 | ||
| 23 | ||
| 22 | ||
| 17 | ||
| 16 | ||
| 15 | ||
| 14 |
